13,976 Shares in Repligen Co. (NASDAQ:RGEN) Purchased by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. purchased a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 13,976 shares of the biotechnology company's stock, valued at approximately $2,080,000.

Several other large investors have also recently made changes to their positions in RGEN. Erste Asset Management GmbH purchased a new stake in Repligen during the third quarter valued at approximately $1,824,000. American Capital Management Inc. lifted its holdings in shares of Repligen by 12.6% during the 3rd quarter. American Capital Management Inc. now owns 379,034 shares of the biotechnology company's stock valued at $56,408,000 after purchasing an additional 42,335 shares during the last quarter. Fred Alger Management LLC boosted its position in shares of Repligen by 29.5% in the 3rd quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company's stock worth $59,313,000 after purchasing an additional 90,831 shares in the last quarter. Braidwell LP grew its stake in Repligen by 22.6% during the 3rd quarter. Braidwell LP now owns 396,781 shares of the biotechnology company's stock worth $59,049,000 after buying an additional 73,272 shares during the last quarter. Finally, Verition Fund Management LLC increased its position in Repligen by 114.7% during the 3rd quarter. Verition Fund Management LLC now owns 5,690 shares of the biotechnology company's stock valued at $847,000 after buying an additional 3,040 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating on the stock. Wells Fargo & Company started coverage on Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target for the company. Benchmark restated a "hold" rating on shares of Repligen in a research note on Monday, August 5th. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research report on Friday, November 22nd. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $190.25.

Repligen Price Performance

Shares of Repligen stock traded up $1.31 during mid-day trading on Monday, reaching $151.85. 170,545 shares of the stock traded hands, compared to its average volume of 662,600. The stock has a market capitalization of $8.51 billion, a PE ratio of -406.85, a PEG ratio of 4.53 and a beta of 0.96. The business has a 50-day moving average of $140.98 and a 200 day moving average of $142.41. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.23 earnings per share. On average, analysts predict that Repligen Co. will post 1.52 EPS for the current year.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company's stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.